Davunetide, also known by its peptide acronym NAP, emerged as a hopeful candidate in the treatment of neurodegenerative diseases characterized by tau protein malfunction, such as Alzheimer’s disease and progressive supranuclear palsy (PSP). This peptide works by stabilizing microtubules—microscopic structural elements critical for maintaining the integrity and function of neural cells. Despite its theoretical appeal, davunetide’s largest clinical trials, particularly in PSP, ended in disappointment, with no clear evidence of therapeutic benefit. However, Gozes and colleagues suspected that the conventional analyses might have missed key sex-based pharmacokinetic distinctions.

What set this investigation apart was its focus on the nuanced biological rhythms that differentiate female subjects. The researchers employed an innovative technique: tagging davunetide with a fluorescent marker to track its absorption and distribution in live mice. Crucially, they didn’t treat female mice as a homogenous group but instead monitored their estrous cycle phases—a rodent’s hormonal cycle analogous to the menstrual cycle in humans. This methodological rigor revealed a striking pattern: female mice during high-estrogen phases (proestrus and estrus) exhibited significantly higher concentrations of davunetide in their brain regions compared to males and to females in low-estrogen phases.

The statistical robustness of these findings was remarkable. In the proestrus phase, for example, differences in brain uptake between males and females were not only substantial but also highly statistically significant, with p-values reaching as low as 0.000004 for head-to-body drug concentration ratios. This suggests that estrogen levels directly impact the bioavailability of davunetide within the central nervous system. The implication is profound—hormonal fluctuations modulate the drug’s journey across the blood-brain barrier, thus influencing its therapeutic potential in ways that conventional trial designs do not account for.

Additional experiments reinforced this conclusion. When female mice were pooled regardless of estrous phase, they still showed consistently higher brain uptake than their male counterparts, underscoring an intrinsic sex difference. Intriguingly, systemic (body-wide) drug concentrations told a different story than cerebral concentrations, hinting that factors regulating central nervous system penetration, such as blood-brain barrier permeability, are under hormonal governance. This uncoupling between peripheral circulation and central uptake complicates the pharmacodynamics and calls for more tailored administration protocols.

Recognizing the translational limitations of rodent models, the authors extended their inquiry to a small human dataset from a past pharmacokinetic study on intranasal davunetide involving healthy adults. Though limited by sample size—only two men and six women—the data hinted at a congruent pattern. Female subjects tended to reach peak nasal and cerebral drug concentrations that were more than double those observed in males. Conversely, males exhibited a markedly longer half-life of the drug, indicating slower clearance. While the sample posed constraints on statistical power, the sex-specific tendencies matched the rodent model’s reflections, reinforcing the biological relevance of these dynamics in humans.

At the biological mechanistic level, the study elucidates a network of interactions linking estrogen, microtubule stability, and blood-brain barrier function. Estrogen is known to modulate vascular tone and endothelial integrity, properties that govern the barrier controlling molecular traffic into the brain. The ADNP protein, from which davunetide is derived, itself undergoes regulation by estrous cycling and reciprocally influences sex hormone pathways. This molecular interplay suggests that davunetide’s neuroprotective effects could hinge critically on hormonal context, complicating straightforward dose-response relationships and potentially explaining the lackluster performance in unstratified clinical trials.

One particularly compelling and somber observation emerged from studies on elderly mice: male rodents exhibited increased mortality during procedures, spotlighting inherent sex differences in vulnerability at advanced ages. Such physiological disparities underscore the urgency of incorporating sex as a biological variable in preclinical and clinical neuropharmacology. The traditional approach, which effectively treats male and female as interchangeable in therapeutic contexts, now seems inadequate and possibly detrimental.

The authors are forthcoming about the limitations of their work. Sample sizes, particularly in human cohorts, remain small and exploratory. Estrous cycle staging involves subjective assessments that may introduce variability, and the studies were not designed to establish definitive therapeutic guidelines. Yet, the methodological transparency and measured interpretation lend credibility to their central argument: averaging out sex and hormonal differences in drug evaluation risks discarding biologically significant variability.

Beyond davunetide, the broader implications of these findings could reverberate throughout neurodegenerative disease research. Alzheimer’s disease disproportionately affects women, manifesting roughly twice as frequently as in men. If sex and hormonal milieu influence neuroprotective agent bioavailability and efficacy, clinical trial failures may partially reflect flawed design rather than true pharmacological ineffectiveness. Integrating precise tracking of sex-specific biology, including hormonal states, may unlock previously obscured therapeutic windows and rescue promising candidates from premature dismissal.

Ultimately, this study challenges a long-standing dogma in drug development: that a “one-size-fits-all” approach to dosing and efficacy assessments is appropriate. Instead, it posits a complex, dynamic landscape where individual biology—including transient hormonal cycles—modulates drug behavior with profound clinical implications. Moving forward, therapeutic strategies must embrace this complexity, aiming to tailor interventions not just to the person but sometimes even to the time within their biological cycle.

Professor Gozes and her team underscore this shift as not merely scientific but ethical: patients deserve precision in medication that respects biological individuality rather than expecting uniform outcomes. The path ahead demands more nuanced clinical trial designs, incorporating sex-specific analyses and hormonal monitoring, to truly optimize neuroprotective treatments and fulfill their potential to alter the trajectory of devastating tauopathies.

As neuroscience continues to unravel the layered intricacies of human biology, this study provokes a vital reconsideration of how we evaluate drugs entering the brain. The fluid interplay between sex hormones, vascular systems, and neuronal scaffolds offers a persuasive argument that “the average patient” is an abstraction—one that risks blunting medical innovation. Therefore, the research presented in Genomic Psychiatry is not just a technical insight into a single peptide’s pharmacokinetics; it is a rallying call to recalibrate our scientific and clinical frameworks around the nuanced realities of sex and hormone-dependent drug bioavailability.

Subject of Research: People

Article Title: Intranasal bioavailability is estrous-cycle regulated: Davunetide as a case study

News Publication Date: 16 June 2026

Web References:
https://doi.org/10.61373/gp026r.0039

References:
Blatt J, Guz LS, Shabat D, Gozes I. Intranasal bioavailability is estrous-cycle regulated: Davunetide as a case study. Genomic Psychiatry 2026. DOI: https://doi.org/10.61373/gp026r.0039. Epub 2026 Jun 16.

Image Credits: Illana Gozes

Keywords

Sex differences, Hormonal regulation, Estrous cycle, Davunetide, ADNP peptide, Blood-brain barrier, Neuroprotection, Tauopathies, Alzheimer’s disease, Pharmacokinetics, Intranasal delivery, Microtubule stabilization

Cannabidiol, a non-psychoactive cannabinoid derived from the Cannabis sativa plant, has been the subject of vibrant scientific interest due to its intriguing neuropharmacological properties. Unlike tetrahydrocannabinol (THC), CBD does not induce intoxicating effects but exhibits a range of potentially therapeutic actions across various central nervous system disorders. Its capacity to modulate drug-associative behaviors is an emerging domain, making it a promising candidate in the battle against cocaine addiction—a condition notoriously difficult to manage with existing interventions.

The study employed an innovative experimental design involving male and female mice, exposed to controlled dosages of cannabidiol prior to cocaine self-administration sessions. By doing so, the team was able to precisely delineate how varying concentrations of CBD influenced cocaine intake, while factoring in the physiological and hormonal distinctions between sexes. This nuanced approach addresses a critical gap in addiction research, where sex-specific responses to pharmacological agents have historically been overlooked, resulting in often incomplete therapeutic strategies.

In male mice, the data revealed a striking dose-dependent reduction in cocaine consumption following CBD administration, pointing to a potential inhibitory effect on the reinforcing properties of cocaine. The researchers hypothesize that CBD’s action may involve modulation of the dopaminergic pathways in the mesolimbic reward system, attenuating cocaine’s rewarding impact at sufficient dosages. Furthermore, this suppression of drug-seeking behavior suggests CBD’s influence on neuroplasticity mechanisms underpinning addiction cycles.

Conversely, female mice exhibited a more complex interaction pattern with CBD and cocaine intake. At lower CBD doses, a paradoxical increase in cocaine consumption was observed, while higher doses mirrored the attenuation effect seen in males. This biphasic response hints at the modulatory role of sex hormones, such as estrogen and progesterone, in shaping CBD’s neuropharmacological influence. The findings underscore the criticality of considering hormonal milieu in addiction therapy, as well as the need to avoid one-size-fits-all dosing regimens.

Delving deeper, the authors explored molecular markers associated with synaptic plasticity and stress responses in brain regions implicated in addiction, including the nucleus accumbens and prefrontal cortex. CBD treatment led to alterations in key signaling molecules, such as brain-derived neurotrophic factor (BDNF) and glucocorticoid receptors, in a sex and dose-dependent fashion. These biochemical shifts potentially mediate behavioral changes, illuminating intricate pathways through which cannabinoids impact addiction-related neurocircuits.

Importantly, the translational relevance of this study lies in its detailed mapping of dose thresholds, below which CBD may inadvertently worsen drug intake in females, and above which protective effects emerge robustly in both sexes. Such findings carry profound implications for clinical applications, emphasizing the necessity of tailored, sex-informed dosing strategies in CBD-based treatments for cocaine addiction. The research also cautions against indiscriminate use of CBD without rigorous understanding of dose-response profiles.

The investigation was fortified by employing progressive ratio paradigms and reinstatement models to mimic relapse behaviors common in human addiction patterns. Across experimental conditions, high-dose CBD consistently curtailed relapse-like cocaine-seeking behaviors in both male and female mice, implicating its potential to reduce the risk of relapse—a cornerstone challenge in addiction medicine. These powerful behavioral outcomes affirm the therapeutic promise of cannabidiol beyond mere primary drug consumption reduction.

This study pioneers exploration into the dual axes of sex specificity and pharmacodynamics in cannabinoid-based addiction interventions, an area ripe for future inquiry. It underscores the complex interplay between neurochemical, hormonal, and behavioral factors that collectively govern substance use disorders. The work thereby sets a new benchmark for precision medicine approaches in addiction therapy and highlights the necessity for sex-differentiated clinical trials.

While preclinical by nature, this research lays robust groundwork for subsequent human studies aimed at validating CBD’s efficacy and safety profiles across genders. Given the rising incidence of cocaine use and the paucity of approved pharmacotherapies, cannabidiol’s repositioning within addiction treatment frameworks could revolutionize the field. The findings resonate with broader initiatives to harness endogenous cannabinoid systems in neuropsychiatric disease management.

However, despite promising results, the authors prudently call for caution and further investigation into long-term effects and potential interactions of CBD with other medications. The nuanced dose-dependent effects observed particularly in females underline the complexity of cannabinoid pharmacology and the need for comprehensive mechanistic studies to fully elucidate CBD’s therapeutic index in addiction contexts.

The mechanistic insights garnered from this research also open prospects for developing synthetic analogs or adjunctive therapies that capitalize on CBD’s beneficial properties while mitigating risks. As addiction remains a multifaceted disorder involving genetic, environmental, and neurobiological determinants, such multi-pronged strategies informed by this foundational work hold considerable promise.

In summary, this seminal study published in Translational Psychiatry reveals that cannabidiol modulates cocaine use in mice through sex-specific and dose-dependent mechanisms. The evidence points to CBD’s potential as an adaptive pharmacotherapeutic agent, capable of reducing drug intake and relapse vulnerability when optimally dosed and personalized according to sex. This advancement propels the field closer to innovative, tailored interventions that may someday alleviate the devastating burden of cocaine addiction worldwide.

Continued research inspired by these findings is anticipated to unravel further intricacies of cannabinoid receptor signaling, hormone interactions, and neuroadaptive processes, ultimately translating to enhanced clinical outcomes. The intersection of cannabinoid pharmacology and addiction neuroscience is thus poised for an exciting era of discovery, where personalized medicine driven by gender-specific insights becomes the standard in combating substance use disorders.

The journey ahead involves bridging preclinical breakthroughs with rigorous clinical validation, fine-tuning administration protocols, and addressing regulatory and ethical considerations inherent in cannabinoid therapeutics. Nevertheless, this work by Llerena and colleagues stands as a testament to the transformative potential of targeted, evidence-based approaches in treating one of the most challenging public health crises of our time.

Subject of Research: Sex and dose-dependent effects of cannabidiol (CBD) on cocaine consumption and relapse behaviors in mice.

Article Title: Sex and dose-dependent effects of cannabidiol on cocaine consumption in mice.

Article References:
Llerena, V., Tic, I., Llach-Folcrà, M. et al. Sex and dose-dependent effects of cannabidiol on cocaine consumption in mice. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-03880-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-03880-3